Share
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
LANCET ONCOLOGY
Coiffier, B; Osmanov, EA; Hong, XN; Scheliga, A; Mayer, J; Offner, F; Rule, S; Teixeira, A; Walewski, J; de Vos, S; Crump, M; Shpilberg, O; Esseltine, DL; Zhu, E; Enny, C; Theocharous, P; van de Velde, H; Elsayed, YA; Zinzani, PL, 2011: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. LANCET ONCOLOGY 12(8), p. 773 - 784, doi: 10.1016/S1470-2045(11)70150-4
CEITEC authors: